{"type":"trials","record":{"id":50748,"source_id":"clinicaltrials-gov","external_id":"NCT04314011","title":"Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty","brief_summary":"The purpose of this clinical study is to answer the questions: 1. Is the proposed intervention safe? 2. Is the proposed intervention effective in improving the healthy status of subjects with aging frailty?","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Shanghai East Hospital","enrollment":30,"countries":["China"],"start_date":"2020-06-01","completion_date":"2022-03-01","last_update_date":"2022-03-17","source_url":"https://clinicaltrials.gov/study/NCT04314011","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:40:48.95077+00:00","last_seen_at":"2026-09-25T06:05:08.502+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"60 Years to 80 Years","comparator":"Control Group","organization":"Shanghai East Hospital","interventions":["Human umbilical cord mesenchymal stem cells（HUC-MSCs）","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety of HUC-MSCs infusion — Within one month post infusion","Difference in rate of decline of Frailty — Baseline, month 1, 3 month and 6 months post infusion","Difference in subject quality of life assessments — Baseline, month 1, month 3 and month 6 post infusion","Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts — Baseline, month 1,…","Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts — Baseline, month 1, month…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Aging Frailty","Human umbilical cord mesenchymal stem cells（HUC-MSCs）","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: stem cell.","quality_checked_at":"2026-09-25T06:05:13.559725+00:00","duplicate_cluster_key":"id:nct04314011","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-06-01 to 2022-03-01","comparator":"Control Group","confidence":"structured-source","population":"ALL · 60 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:05:08.535Z","intervention":["Human umbilical cord mesenchymal stem cells（HUC-MSCs）","Placebo"],"participants":30,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety of HUC-MSCs infusion — Within one month post infusion","Difference in rate of decline of Frailty — Baseline, month 1, 3 month and 6 months post infusion","Difference in subject quality of life assessments — Baseline, month 1, month 3 and month 6 post infusion","Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts — Baseline, month 1,…","Changes in cellular components of the immune system between the HUC-MSC and placebo cohorts — Baseline, month 1, month…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"stem-cells","is_published":true,"match_reasons":["Title contains controlled term: stem cell.","Source terminology contains: stem cell.","Title supplies longevity context: aging, frailty.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Stem cells","slug":"stem-cells"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/50748","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}